3-溴萘-1-甲醛 | 303779-66-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 中文名称: 3-溴萘-1-甲醛
• 英文名称: 3-bromo-1-naphthaldehyde
• 英文别名: 3-Bromonaphthalene-1-carboxaldehyde；3-bromonaphthalene-1-carbaldehyde
• CAS: 303779-66-0
• 化学式: C₁₁H₇BrO
• 分子量: 235.08
• InChiKey: VMPJCCFHSYZCJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-溴萘-1-甲醛 在 sodium sulfate 、 bis(dibenzylideneacetone)-palladium⁽⁰⁾ 作用下， 以 乙醇 、 1,2-二氯乙烷 为溶剂， 反应 12.0h， 生成 3-bromo-1-formylnaphthalen-2-yl acetate
  参考文献：
  名称：

  Palladium-Catalyzed Regiospecific peri- and ortho-C–H Oxygenations of Polyaromatic Rings Mediated by Tunable Directing Groups

  摘要：

  DOI：

  10.1021/acs.orglett.0c03701
• 作为产物：
  描述：

  3-溴-1-甲基萘 在 N-溴代丁二酰亚胺(NBS) 、 十二/十四烷基二甲基氧化胺 、 过氧化苯甲酰 作用下， 以 四氯化碳 、 二氯甲烷 、 二甲基亚砜 为溶剂， 反应 18.0h， 生成 3-溴萘-1-甲醛
  参考文献：
  名称：

  Palladium-Catalyzed Regiospecific peri- and ortho-C–H Oxygenations of Polyaromatic Rings Mediated by Tunable Directing Groups

  摘要：

  DOI：

  10.1021/acs.orglett.0c03701

文献信息

• [EN] CYCLOPROPANAMINE COMPOUND AND USE THEREOF<br/>[FR] COMPOSÉ DE CYCLOPROPANAMINE ET SON UTILISATION
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2015156417A1

  公开（公告）日：2015-10-15

  The present invention provides a compound having a lysine-specific demethylase-1 inhibitory action, and useful as a medicament such as a prophylactic or therapeutic agent for schizophrenia, developmental disorders, particularly diseases having intellectual disability (e.g., autistic spectrum disorders, Rett syndrome, Down's syndrome, Kabuki syndrome, fragile X syndrome, Kleefstra syndrome, neurofibromatosis type 1, Noonan syndrome, tuberous sclerosis), neurodegenerative diseases (e.g., Alzheimer's disease, Parkinson's disease, spinocerebellar degeneration (e.g., dentatorubural pallidoluysian atrophy) and Huntington's disease), epilepsy (e.g., Dravet syndrome) or drug dependence, and the like. A compound represented by the formula wherein each symbol is as defined in the present specification, or a salt thereof.

  本发明提供了一种具有赖氨酸特异性去甲基化酶-1抑制作用的化合物，可用作药物，例如作为精神分裂症、发育障碍，特别是智力障碍性疾病（例如自闭症谱系障碍、雷特综合征、唐氏综合征、歌舞综合征、脆性X综合征、克里夫斯特拉综合征、神经纤维瘤病1型、努南综合征、结节性硬化症等）神经退行性疾病（例如阿尔茨海默病、帕金森病、脊髓小脑变性疾病（例如小脑纹状体苍白松解性萎缩）和亨廷顿病）、癫痫（例如德拉综合征）或药物依赖等的预防或治疗剂。化合物如下式所示，其中每个符号如本说明书中定义，或其盐。
• Overcoming <i>peri</i>- and <i>ortho</i>-selectivity in C–H methylation of 1-naphthaldehydes by a tunable transient ligand strategy
  作者：Yujian Mao、Jing Jiang、Dandan Yuan、Xiuzhen Chen、Yanan Wang、Lihong Hu、Yinan Zhang

  DOI：10.1039/d1sc05899a

  日期：——

  Aiming to introduce this smallest alkyl handle, a highly regioselective peri- and ortho-C–H methylation of 1-naphthaldehyde by using a transient ligand strategy has been developed. A series of methyl-substituted naphthalene frameworks have been prepared in moderate to excellent yields. Mechanistic studies demonstrate that peri-methylation is controlled by the higher electronic density of the peri-position

  甲基广泛存在于生物活性分子中，位点特异性甲基化已成为其结构功能化的重要策略。为了引入这种最小的烷基手柄，我们开发了一种通过使用瞬时配体策略对 1-萘醛进行高度区域选择性的邻位和邻位-C–H 甲基化的方法。一系列甲基取代的萘骨架已以中等至优异的产率制备。机理研究表明，邻甲基化是由1-萘醛邻位较高的电子密度以及中间5,6-稠合双环钯环的形成控制的，而实验研究和理论计算推断，5元环1-萘醛邻位的铱环通过周围环和邻环之间的相互转化导致能量上有利的邻甲基化。重要的是，为了证明该方法的合成效用，我们证明该策略可以作为合成多取代萘基生物活性分子和天然产物的平台。
• Hepatitis C Virus Inhibitors
  申请人：Hiebert Sheldon

  公开号：US20100080770A1

  公开（公告）日：2010-04-01

  Hepatitis C virus inhibitors having the general formula are disclosed. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.

  揭示了具有一般式的丙型肝炎病毒抑制剂。还揭示了包含这些化合物的组合物以及使用这些化合物抑制HCV的方法。
• [EN] CYCLIC AMINE DERIVATIVES, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM<br/>[FR] DERIVES D'AMINE CYCLIQUES, PROCEDES DE PREPARATION DE CEUX-CI ET COMPOSITIONS PHARMACEUTIQUES LES CONTENANT
  申请人：GLAXO GROUP LTD

  公开号：WO2004099143A1

  公开（公告）日：2004-11-18

  A compound of formula (I) wherein R represents a radical selected from i) ii) iii) iv) where the substituents R1, R2, R3, R4, R4, R7 and the indices m, n and p are as defined in the description; or pharmaceutically acceptable salts and solvates thereof; processes for their preparation to pharmaceutical compositions containing them and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.

  式（I）的化合物，其中R代表从i）ii）iii）iv）中选择的基团，其中取代基R1、R2、R3、R4、R5、R6、R7和指数m、n和p如描述中所定义；或其药学上可接受的盐和溶剂；它们的制备方法到含有它们的药物组合物以及它们在治疗由速效肽激酶介导的病症和/或通过选择性抑制血清素再摄取转运蛋白介导的病症中的应用。
• Cyclic amine derivatives, processes for their preparation, and pharmaceutical compositions containing them
  申请人：Alvaro Giuseppe

  公开号：US20070073061A1

  公开（公告）日：2007-03-29

  A compound of formula (I) wherein R is a radical selected from in which R 7 is halogen, cyano, C 1-4 alkyl, C 1-4 alkoxy, trifluoromethyl or trifluoromethoxy; p is an integer from 0 to 3; R 1 is hydrogen, halogen, cyano, C 2-4 alkenyl, C 1-4 alkyl optionally substituted by halogen, cyano or C 1-4 alkoxy; R 2 is hydrogen or C 1-4 alkyl; R 3 and R 4 independently are hydrogen, C 1-4 alkyl or R 3 together with R 4 is C 3-7 cycloalkyl; R 5 is phenyl substituted by 1 to 3 groups independently selected from trifluoromethyl, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC 1-4 alkyl, naphthyl substituted by 1 to 3 groups independently selected from trifluoromethyl, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC 1-4 alkyl, a 9 to 10 membered fused bicyclic heterocyclic group substituted by 1 to 3 groups independently selected from trifluoromethyl, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC 1-4 alkyl or R 5 is a 5 or 6 membered heteroaryl group substituted by 1 to 3 groups independently selected from trifluoromethyl, C 1-4 alkyl, cyano, C 1-4 alkoxy, trifluoromethoxy, halogen or (SO)rC 1-4 alkyl; R 6 is hydrogen or (CH 2 )qR 8 ; R 8 is hydrogen, C 3-7 cycloalkyl, C 1-4 alkoxy, amine, C 1-4 alkylamine, (C 1-4 alkyl) 2 amine, OC(O)NR 9 R 10 or C(O)NR 9 R 10 ; R 9 and R 10 independently are hydrogen, C 1-4 alkyl or C 3-7 cycloalkyl; m is zero or 1; n is 1 or 2; q is an integer from 1 to 4; r is 1 or 2; or pharmaceutically acceptable salts and solvates thereof; processes for their preparation to pharmaceutical compositions containing them and their use in the treatment of conditions mediated by tachykinins and/or by selective inhibition of serotonin reuptake transporter protein.

  化合物的结构式为（I），其中R是选择自以下基团的基团，其中R7是卤素、氰基、C1-4烷基、C1-4烷氧基、三氟甲基或三氟甲氧基；p是从0到3的整数；R1是氢、卤素、氰基、C2-4烯基、C1-4烷基（可选择性地被卤素、氰基或C1-4烷氧基取代）；R2是氢或C1-4烷基；R3和R4分别是氢、C1-4烷基或R3与R4结合形成C3-7环烷基；R5是苯基，其上1到3个基团分别选择自三氟甲基、C1-4烷基、氰基、C1-4烷氧基、三氟甲氧基、卤素或（SO）rC1-4烷基；萘基，其上1到3个基团分别选择自三氟甲基、C1-4烷基、氰基、C1-4烷氧基、三氟甲氧基、卤素或（SO）rC1-4烷基；或9到10个成员的融合双环杂环基团，其上1到3个基团分别选择自三氟甲基、C1-4烷基、氰基、C1-4烷氧基、三氟甲氧基、卤素或（SO）rC1-4烷基；R5也可以是5或6个成员的杂芳基团，其上1到3个基团分别选择自三氟甲基、C1-4烷基、氰基、C1-4烷氧基、三氟甲氧基、卤素或（SO）rC1-4烷基；R6是氢或（CH2）qR8；R8是氢、C3-7环烷基、C1-4烷氧基、胺、C1-4烷基胺、（C1-4烷基）2胺、OC（O）NR9R10或C（O）NR9R10；R9和R10分别是氢、C1-4烷基或C3-7环烷基；m为零或1；n为1或2；q是从1到4的整数；r为1或2；或其药学上可接受的盐和溶剂；制备它们的方法，含有它们的药物组合物以及它们在治疗由Tachykinins和/或通过选择性抑制血清素再摄取转运蛋白介导的疾病中的用途。